At Kinoxis we are passionate about fostering relationships. We acknowledge and appreciate the unique perspective and experience of every patient, family member, loved one, and advocate.
We are committed to developing safe and effective medicines as quickly as possible. We recognise the importance of improving quality of life, for patients and their loved ones.
KTX-201: A Multi-centre, Phase 2a, Double-blind, Placebo-controlled, Randomised Study to Examine the Safety, Tolerability, and Efficacy of KNX100 in the Treatment of Subjects with Agitation Associated with Dementia.
This ongoing study will assess the safety, tolerability, and efficacy of KNX100 in patients with agitation associated with Dementia.
© Kinoxis Therapeutics | All Rights Reserved | Website by Graphink Design and Integrale Marketing